Prospective registry for multifactorial risk factor assessment, enrolling consecutive ischemic stroke/transient ischemic attack patients with structural, inflammatory, or arrhythmogenic cardiac disease, who are admitted to our University Hospital.
The prospective registry shall provide new insights into the multiple associations, and respective therapeutic implications of cardio-vascular risk factors and stroke. For that reason consecutive patients with ischemic stroke/transient ischemic attack (brain, spinal cord, or retinal) and structural (e.g. patent foramen ovale), septic or aseptic endocarditis or myocarditis, or supra-ventricular or ventricular arrhythmia, who are admitted to our University Hospital, are enrolled. Multifactorial assessment of risk factors is based on medical history, laboratory biomarkers, electrocardiogram incl. cardiac autonomic function analysis, and (long-term) cardiac rhythm monitoring, as well as transthoracic and transesophageal echocardiography. Inclusion of follow-up visits permit longitudinal and prognostic evaluation of routine diagnostic and therapeutic interventions for secondary stroke prevention (e.g. implantable loop recorders or interventional closure of patent foramen ovale).
Study Type
OBSERVATIONAL
Enrollment
878
Rate of any stroke
Recurrent ischemic stroke or intracranial hemorrhage during follow-up
Time frame: ≥ 12 months
Rate of mortality
Death from any cause during follow-up
Time frame: ≥ 12 months
Rate of ischemic stroke
Ischemic stroke recurrence during follow-up
Time frame: ≥ 12 months
Rate of transient ischemic attack
Transient ischemic attack recurrence during follow-up
Time frame: ≥ 12 months
Rate of systemic embolism
Systemic embolism during follow-up
Time frame: ≥ 12 months
Rate of myocardial infarction
Myocardial infarction during follow-up
Time frame: ≥ 12 months
Rate of intracranial hemorrhage
Intracranial hemorrhage during follow-up
Time frame: ≥ 12 months
Rate of major Bleedings
Major Bleedings during follow-up
Time frame: ≥ 12 months
Rate of major or clinically relevant non-major bleedings
Major or clinically relevant non-major bleedings during follow-up
Time frame: ≥ 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rate of serious adverse events
Serious adverse events during follow-up
Time frame: ≥ 12 months
Rate of new-onset atrial fibrillation
Detection of atrial fibrillation during follow-up
Time frame: ≥ 12 months
modified Rankin Score; range from 0 to 6, with '0' indicating the best outcome (i.e. no deficit), and '6' the worst outcome (i.e. death)
modified Rankin Scale score at follow-up
Time frame: ≥ 12 months